Merck's consistent dividend payments over 34 years, healthy balance sheet, and attractive valuation highlight its investment ...

The FDA has approved a new triple-drug antibiotic from Merck & Co, but the company and regulator have cautioned it should only be prescribed for last-ditch use. Recarbrio – which based on ...

Are you a print subscriber? Activate your account. By Garett Sloane - 2 hours 35 min ago By Gillian Follett - 2 hours 35 min ago By E.J. Schultz - 2 hours 35 min ago By Jack Neff - 2 hours 35 min ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

RAHWAY, N.J. & CAMBRIDGE, Mass., October 28, 2024--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Moderna, Inc. (Nasdaq: MRNA), today ...

But by the end of the decade, the company should be on its way to replacing Keytruda as its now sold with a new formulation of the medicine. And Merck's business extends beyond this single product.

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Commission (EC) has approved two new indications for KEYTRUDA ® (pembrolizumab), Merck ...

If you want to stay updated on the latest options trades for Merck & Co, Benzinga Pro gives you real-time options trades alerts. Benzinga is an innovative financial news outlet that has become the ...

Merck KGaA said it’s seeing the beginning of a post-Covid pandemic rebound in life sciences as it reaffirmed the group’s sales and profit guidance for the full year. The German science and ...

Our meteorologists are ready. Sign up for the NBC 6 Weather newsletter to get the latest forecast in your inbox. Merck also lowered its adjusted profit guidance to a range of $7.72 to $7.77 per ...